Anecdotal evidence that cannabis preparations have medical benefits together with the
discovery of the psychotropic plant cannabinoid Δ9-tetrahydrocannabinol (THC) initiated …

Introduction: Cannabidiol (CBD) as Epidiolex®(GW Pharmaceuticals) was recently
approved by the US Food and Drug Administration (FDA) to treat rare forms of epilepsy in …

The endocannabinoid system (ECS) is composed of two G protein-coupled receptors
(GPCRs), the cannabinoid CB1 and CB2 receptors, and the two main endogenous lipid …

Palmitoylethanolamide (PEA) has emerged as a potential nutraceutical, because this
compound is naturally produced in many plant and animal food sources, as well as in cells …

Recent years have yielded significant advances in our understanding of microglia, the
immune cells of the central nervous system (CNS). Microglia are key players in CNS …

Multiple sclerosis is the most common inflammatory demyelinating disease of the central
nervous system, caused by an autoimmune response against myelin that eventually leads to …

This study was aimed to investigate whether treatment with purified cannabidiol (CBD) may
counteract the development of experimental multiple sclerosis (MS), by targeting the …

Many people with MS (pwMS) use unregulated cannabis or cannabis products to treat the
symptoms associated with the disease. In line with this, Sativex, a synthetic combination of …

Neurological disorders such as neurodegenerative diseases or traumatic brain injury are
associated with cognitive, motor and behavioural changes that influence the quality of life of …

The medicinal properties of cannabis and cannabinoid‐derivative are entirely investigated
and known. In addition, the identification of psychotropic plant cannabinoids has led to more …